ABT vs NVCR
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. NVCR: Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy.
Side-by-side fundamentals
| Metric | ABT | NVCR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $104.49 | $17.03 | |
| Market cap as of 2026-07-29 | $182.0B | $2.0B | |
| P/E as of 2026-07-29 | 33.63 | n/a | |
| PEG as of 2026-07-29 | 2.66 | n/a | |
| Net margin as of 2026-07-29 | +11.7% | -21.3% | ABT higher |
| Gross margin as of 2026-07-29 | +56.8% | +76.1% | NVCR higher |
| Operating margin as of 2026-07-29 | +15.8% | -22.1% | ABT higher |
| ROE as of 2026-07-29 | +12.2% | -44.0% | ABT higher |
| ROA as of 2026-07-29 | +6.9% | -15.8% | ABT higher |
| Debt / equity as of 2026-07-29 | 0.65 | 0.58 | NVCR lower |
| Revenue growth (YoY) as of 2026-07-29 | +8.1% | +10.9% | NVCR higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +6.8% | NVCR higher |
| Dividend yield as of 2026-07-29 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-29 | 0.57 | 1.00 | |
| 1-year return as of 2026-07-27 close | -17.4% | +41.4% | NVCR higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.